- Home
- SABA vs ADAG Comparison
SABA vs ADAG Comparison
Compare SABA & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SABA | ADAG |
|---|---|---|
| Founded | 1988 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.7M | 222.2M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SABA | ADAG |
|---|---|---|
| Price | $7.76 | $1.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $9.91 |
| AVG Volume (30 Days) | 74.5K | ★ 306.2K |
| Earning Date | 01-01-0001 | 08-12-2026 |
| Dividend Yield | ★ 12.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $129.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.57 | $1.44 |
| 52 Week High | $8.92 | $4.85 |
Technical Indicators
Market Signals| Indicator | SABA | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 33.29 |
| Support Level | $7.61 | N/A |
| Resistance Level | $8.40 | $3.50 |
| Average True Range (ATR) | 0.08 | 0.23 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 75.00 | 4.94 |
Price Performance
Historical ComparisonAbout SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.